Valeant Pharmaceuticals International v. Jerney Case Brief Summary | Law Case Explained
The Rise and Fall of Valeant Pharmaceuticals: Business Case Study Explained
The Valeant Fraud Explained
From Darling to Scandal: The Valeant Pharmaceuticals Story
Valeant Pharmaceuticals in crosshairs of U.S. Congress
Citron Research Founder: What Valeant's Doing 'Sounds Illegal'
Valeant changes name to Bausch Health Companies, CEO explains why
Here’s What Valeant Pharmaceuticals Said on Its Emergency Conference Call to Investors
Key things investors need to know about Valeant | The Bottom Line
Valeant Says It's Under Investigation by SEC
Valeant Scandal: How Valeant Scammed People Legally | Beyond Wonder
Valeant: Damaged Goods or Deeply Discounted Drug Company?
Valeant CEO on Drug Price Hikes: We Made Mistakes
Valeant shares continue to plunge
Valeant Suffers Biggest Drop on Record, What's Next?
New To Valeant? Here's What Happened
Bill Ackman defends Valeant
Charlie Munger: Sewer too light a word for Valeant
One year later, Chanos is still shorting Valeant
Ackman: Plan to Discuss Drug Prices With Valeant Board
Pharma CEO Admits: Our Business is Profit, Not Helping Sick People
Horizon Pharma CEO: Not A Mini-Valeant | Mad Money | CNBC
Valeant's Response to Fraud Claim Is 'Amateurish, Citron Founder Says
Nestle gets deeper into dermatology with Valeant deal - economy
Valeant Pharmaceuticals International Marks World Sight Day at the NYSE
Valeant Pharmaceuticals, Artis Reit, Boyd Group Income Fund - BNN
Bill Ackman Sells Valeant Stake After $2.8 Billion Loss
A tumultuous year for Valeant Pharmaceuticals
Ackman: Allergan tried to 'malign' Valeant with false statements
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
Forensic Talk; NetFlix “Dirty Money” Valeant Drugs
Safkhet Capital's Quadir Is Still Short Valeant
Valeant Pharmaceuticals / Drug Price Profiteering
Valeant Pharmaceuticals CEO Returns, But Company Postpones Release of Q4 Results
Controversial Valeant-linked pharmacy closing its doors
The Valeant Disaster And Why I Switched To Trend Following
Short-Seller Quadir Makes the Bear Case for Tesla
Valeant Pharmaceuticals Shares Tank on Weak Guidance
Short Seller Famous for Bet Against Valeant Targets Tesla
Analysts Eye Valeant Pharmaceuticals as Much-Anticipated Earnings Set for Release
M&A's Hard Lessons Learned From 3G, Valeant & SoftBank
SBU MBA 610 Project - Valeant Pharmaceuticals
GlaxoSmithKline, Valeant Pharma Receive EU Approval For Seizure Drug
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
Valeant May Once Again Need to Lower Its 2016 Earnings Outlook
Casey Questions Valeant Execs on Dramatic Drug Price Increases
Valeant Pharmaceuticals Misses Earnings Estimates but Posts Better-Than-Expected Guidance
Former Valeant and Philidor Executives Charged In Manhattan For Illegal Fraud And Kickback Scheme
Conference Call Scheduled Today for Valeant Pharmaceuticals
VALEANT PHARMACEUTICALS INTERNATIONAL INC. - Lauréat régional 2016 - Laval
Here's Why Shares of Valeant are Higher in Monday's Trading Session
A timeline of Valeant’s fall from the top
What Jim Cramer Thinks About Valeant Pharmaceuticals Shares